Highest-materiality recent filing
Sunshine Biopharma reduces Series B warrant exercise price to $1.2202 after ATM sales
Exercise price of Series B warrants reduced to $1.2202 due to recent common stock sales under ATM offering.
Sunshine Biopharma enters $4M ATM equity facility with Aegis Capital
Up to $4M of common stock may be sold at-the-market through Aegis Capital as exclusive agent.
Sunshine Biopharma settles dispute with former Nora Pharma president for CAD$1.5M
Company to pay CAD$1.5M (approx US$1.06M) to Malek Chamoun to settle all claims and cross-claims.
Majority shareholder approves >20% stock issuance at discount; warrant adjustments allowed
CEO Dr. Steve N. Slilaty, holding ~86% voting power, approved issuance of >20% of outstanding shares at discount to Nasdaq min price.
Sunshine Biopharma closes $6.0M public offering with up to $12M additional warrant proceeds
Gross proceeds $6.0M from 12,000,000 units at $0.50/unit; closed May 19, 2026.
Sunshine Biopharma reports FY 2025 revenue $36.3M (+4.1% YoY), net loss $5.98M
Revenue $36.31M vs $34.87M in 2024; gross profit $12.26M up from $10.67M.
Engaged Aegis Capital on March 6, 2026 to induce exercise of outstanding warrants on best-efforts basis.
Majority shareholder approves reverse stock split up to 1-for-10 for Sunshine Biopharma
Dr. Steve N. Slilaty, holding ~96% voting power, approved by written consent a reverse split of common stock up to 1-for-10.
Sunshine Biopharma COO Dr. Abderrazzak Merzouki resigns effective immediately
Dr. Abderrazzak Merzouki resigned as COO of Sunshine Biopharma on February 5, 2026, effective immediately.
All five director nominees elected: Dr. Slilaty, Sebaaly, Kiderchah, Natan, Keller received over 130M votes for.
Sunshine Biopharma dismisses Bush & Associates, appoints M&K CPAS as auditor effective Sept 24, 2025
Dismissed Bush & Associates CPA LLC as independent auditor on Sept 24, 2025; no prior disagreements or reportable events.
Sunshine Biopharma Q1 revenue up 18% to $8.9M; net loss narrows
Revenue of $8.9 million in Q1 2025, up 18% from $7.5M in Q1 2024.
Sunshine Biopharma closes $2.46M registered direct offering of common stock and pre-funded warrants
Gross proceeds of approximately $2.46M from sale of 1,188,404 shares of common stock (or pre-funded warrants) at $2.07 per share.
Sunshine Biopharma FY2024 revenue $34.9M (+45% YoY); net loss widens to $5.1M
Revenue $34.9M in FY2024, up 45% from $24.1M in FY2023; gross profit $10.7M.
Sunshine Biopharma appoints Michel Roy as Chief Commercial Officer
Michel Roy appointed CCO effective Jan 13, 2025; initial base salary of $400,000 CAD annually.
Sunshine Biopharma annual meeting: all director nominees elected with >130M votes, auditor ratified
Dr. Steve Slilaty, Dr. Merzouki, Dr. Kiderchah, Mr. Natan, Dr. Keller each elected with over 130M votes FOR.
Sunshine Biopharma Q3 2024 revenues up 42% YoY; net loss widens 84% in quarter
Q3 2024 gross revenues $8.44M, up 42% from $5.96M in Q3 2023; YTD revenues $25.28M, up 54%.
Sunshine Biopharma enters new employment agreements with CEO, CFO, COO; CEO severance of $14M USD
CEO Dr. Slilaty: $543,753 CAD base salary, 5% or CPI annual increase, $14M USD severance for termination without cause or for good reason.
Received Nasdaq letter confirming compliance with Bid Price Rule (Listing Rule 5550(a)(2)).
Sunshine Biopharma Q2 revenue $9.3M (+67% YoY); net loss narrows 45% to $(494K)
Q2 gross revenue $9,303,067, up 67% from $5,560,865 in Q2 2023.
Sunshine Biopharma announces 1-for-20 reverse stock split, effective Aug 8
1-for-20 reverse stock split effective August 8, 2024; each share converted to one-twentieth of a share.
Majority shareholder approves up to 60-for-1 reverse stock split
Dr. Steve Slilaty, holding 84.8% voting power, approved reverse split by written consent.
Sunshine Biopharma gets Nasdaq bid-price extension to Aug 26, 2024
Received Nasdaq Hearings Panel exception until August 26, 2024 to regain minimum bid price compliance.
All Series A Warrants exercised by holders as of June 11, 2024
Series A Warrants issued on Feb 15, 2024 fully exercised as of June 11, 2024.
Nasdaq notifies Sunshine Biopharma of delisting due to warrant dilution
Nasdaq staff determined to delist SBFM under Rule 5101 citing public interest concerns over Series A warrant cashless exercise provision.
Sunshine Biopharma Q1 2024 revenue up 54% to $7.54M; net loss narrows to $1.28M
Q1 2024 revenue of $7,541,046, a 54% increase from $4,894,053 in Q1 2023.
Sunshine Biopharma appoints Bush & Associates as new auditor, eff. May 7, 2024
Bush & Associates CPA LLC engaged as independent registered public accounting firm as of May 7, 2024.
Sunshine Biopharma dismisses auditor BF Borgers after SEC permanent ban
BF Borgers CPA, PC was dismissed as independent auditor after SEC settled charges and permanently banned the firm.
Sunshine Biopharma effects 1-for-100 reverse stock split effective April 17, 2024
1-for-100 reverse split of common stock (SBFM) and warrants (SBFMW) effective April 17, 2024.
Sunshine Biopharma reports 2023 sales $24.1M, loss per share improves to -$0.19
Sales grew to $24,092,787 in 2023 from $4,345,603 in 2022; average quarter-over-quarter growth of 14%.
Sunshine Biopharma CEO buys voting-preferred shares for $10K; 1-for-200 reverse split approved
CEO Steve Slilaty purchased 100,000 Series B Preferred shares for $10,000, each with 1,000 votes.
Sunshine Biopharma receives Nasdaq delisting notice; stock at $0.10 or less for 10 days
Nasdaq staff determined common stock bid price <= $0.10 for ten consecutive days as of Feb 27, 2024.
Majority shareholder approves warrant adjustments for Sunshine Biopharma
Dr. Steve Slilaty (CEO, 58.3% voting power) approved written consent on Feb 13, 2024.
Sunshine Biopharma closes ~$10M underwritten public offering of units with warrants
71,428,571 Units priced at $0.14/Common Unit and $0.139/Pre-Funded Unit; gross proceeds ~$10.0M.
Sunshine Biopharma repurchases and cancels warrants for ~21.6M shares for $3.14M total
Bought back May 2023 warrants for 11,904,762 shares from Armistice Capital for $2,361,596; warrants cancelled.
Sunshine Biopharma appoints new COO and Chief Development Officer at annual meeting
Marc Beaudoin appointed COO; Malek Chamoun appointed Chief Development Officer, effective Jan 25, 2024.
Sunshine Biopharma annual meeting: directors elected, reverse split up to 1:40 approved
All five director nominees elected with >16M votes each; broker non-votes 5.04M.
Gross revenues $5,957,668 for Q3 2023, up from $132,808 a year earlier, driven by Nora Pharma Inc. acquisition.
Sunshine Biopharma terminates Adva-27a research agreement with JGH after unfavorable lab results
Termination of Research Agreement with Jewish General Hospital effective Dec 2, 2023.
Sunshine Biopharma amends warrants to $0.11 exercise price and removes CEO voting restriction
Reduces exercise price of outstanding Tradeable Warrants to $0.11; Pre-Funded Warrants to $0.001 per share.
Sunshine Biopharma warrant holders approve amendment reducing exercise price to $0.11
Warrant holders approved amendment to reduce Tradeable Warrants exercise price to $0.11.
Sunshine Biopharma gets 180-day Nasdaq bid-price compliance extension to March 18, 2024
Received 180-day Nasdaq extension until March 18, 2024 to meet $1.00 min bid price.
Sunshine Biopharma Q2 2023 revenues jump 3,600% YoY to $5.56M
Revenues of $5,560,865 for Q2 2023, a 3,600% increase over Q2 2022.
Sunshine Biopharma closes $5M private placement, issues shares and warrants
Issued 5,952,381 units at $0.84/unit; each unit = 1 share (or pre-funded warrant) + 2 warrants at $0.59 exercise price.
Sunshine Biopharma reports Q1 2023 revenues of $4.89M, up 2,100% YoY
Gross revenues of $4,894,053 for Q1 2023, a 2,100% increase over Q1 2022, driven by Nora Pharma acquisition.
Sunshine Biopharma amends bylaws to set quorum at one-third of outstanding shares
Quorum for shareholder meetings now one-third of outstanding common voting stock.
Sunshine Biopharma receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified SBFM on March 24, 2023, of bid price non-compliance under Rule 5550(a)(2).
Sunshine Biopharma signs exclusive worldwide license with U. Arizona for PLpro COVID-19 treatment
License grants exclusive worldwide rights to PLpro protease inhibitors of SARS-CoV-2 (COVID-19).
Sunshine Biopharma regains Nasdaq minimum bid price compliance
Received Staff notice on Feb 9, 2023, confirming compliance with $1 bid price rule.
3-year agreement to advance Adva-27a through IND-enabling studies; JGH paid fair market value for services.
On January 13, 2025, Sunshine Biopharma Inc. (the “Company”) appointed Mr. Michel Roy as the Company’s Chief Commercial Officer.
Previously, Dr. Merzouki had held the position of Chief Operating Officer.
Malek Chamoun, age 39 , was appointed as our Chief Development Officer in January 2024.
Marc Beaudoin, age 57, was appointed as our Chief Operating Officer in January 2024.
The Board added Messrs. Andrew Telsey, JD Kish and Dr. Rabi Kiderchah to serve as directors
The Board added Messrs. Andrew Telsey, JD Kish and Dr. Rabi Kiderchah to serve as directors
The Board added Messrs. Andrew Telsey, JD Kish and Dr. Rabi Kiderchah to serve as directors
Max materiality 0.90 · Median 0.55 · Most common event other_material